- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05194735
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Phase I/II Study of Autologous T Cells Engineered Using the Sleeping Beauty System to Express T-Cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects With Solid Tumors
A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors. The study ended during Phase I Arm A after 8 subjects were treated. Arm B and Phase II were not initiated, and the maximum tolerated dose or recommended Phase II dose was not determined.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors.
Screening was initially conducted under TCR001-002. TCR001-201 Protocol Amendment 4, approved by the IRB on 20 January 2023 and implemented at the site in February 2023, incorporated HLA typing and tumor neoantigen screening into TCR001-201. Eligibility required a matching tumor mutation and HLA restriction represented in the Sponsor's clinical TCR library.
The Phase I part of this study is a prospective, open-label, dose-escalation study of TCR-T cell drug product in patients with progressive or recurrent solid tumors who have failed standard therapy. The Phase II part is a prospective, open-label, single dose portion of the study. The planned Phase II portion was to begin after determination of the maximum tolerated dose or recommended Phase II dose in Phase I. The program closed during Phase I Arm A before that determination. Arm B and Phase II were not initiated, and no subject received interleukin-2 under this study.
Subjects with one of the following histologically confirmed solid tumors will be included:
- Cohort 1: Gynecologic cancer (e.g., ovarian, endometrial)
- Cohort 2: Colorectal cancer
- Cohort 3: Pancreatic cancer
- Cohort 4: Non-small cell lung cancer (NSCLC); NSCLC includes but is not limited to squamous cell carcinoma, adenosquamous carcinoma or adenocarcinomas
- Cohort 5: Cholangiocarcinoma
Subject must have a tumor mutation and HLA typing combination that matches to at least one of the following TCRs in the Alaunos' library (mutation & HLA type):
- KRAS G12D & HLA-A*11:01
- KRAS G12D & HLA-C*08:02
- KRAS G12V & HLA-A*11:01
- KRAS G12V & HLA-C*01:02
- TP53 R175H & HLA-A*02:01
- TP53 R175H & HLA-DRB1*13:01
- TP53 R248W & HLA-A*68:01
- TP53 Y220C & HLA-A*02:01
- TP53 Y220C & HLA-DRB3*02:02
- EGFR E746-A750del & HLA-DPA1*02:01, DPB1*01:01
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-
Patients who have completed the HLA Typing and Tumor Neoantigen Identification Protocol (TCR001-002) and for whom a TCR(s) matching the subject's somatic mutation(s) and HLA type restriction combination is available in Alaunos' Clinical TCR library
-
Patients who have previously received at least one line of standard systemic therapy for their advanced/metastatic cancer and have either progressed, recurred, or were intolerant to the previous treatment. Specifically:
-
Subgroup 1. Gynecologic cancers (i.e., ovarian or endometrial):
- Ovarian cancer
- Endometrial cancer
-
Subgroup 2. Colorectal cancer
-
Subgroup 3. Pancreatic cancer
-
Subgroup 4. Non-small cell lung cancer (NSCLC)
-
Subgroup 5. Cholangiocarcinoma
-
-
Patients must have evaluable or measurable disease per RECIST 1.1 with at least one lesion that can be measured that is not the biopsied lesion.
-
Patients must be able to provide written informed consent.
-
Patients must be age ≥ 18 years.
-
Clinical Performance Status of ECOG 0 or 1. Approval from the Alaunos Medical Monitor is required for ECOG of 2.
-
Patient must be willing and able to provide written informed consent for the long-term follow-up protocol (TCR001-202) for up to 15 years post TCR-T Cell drug product infusion per FDA requirements.
-
Adequate bone marrow reserves as assessed by the following hematology laboratory criteria:
-
Adequate major organ system function
-
A washout period must have elapsed since completion of any prior systemic therapy, and apheresis with guidelines as follows (windows other than what is listed below should be allowed only after consultation with the Medical Monitor); subjects' non-hematologic toxicities from any prior systemic therapy must have recovered to ≤ Grade 1 (with the exception of neuropathy and alopecia) or baseline prior to starting the protocol's therapy.
-
Patients may have undergone minor surgical procedures or limited-field radiotherapy provided any major organ toxicities have recovered to ≤ Grade 1.
-
Female patients must not be pregnant or breastfeeding.
Exclusion Criteria:
- Patients with known active CNS metastases
- Concurrent systemic steroid therapy
- Any form of primary immunodeficiency
- Patients who have decreased immune competence
- History of severe immediate hypersensitivity reaction to cyclophosphamide, fludarabine, aldesleukin or bendamustine
- Severe chronic respiratory condition
- History of a bleeding disorder or unexplained major bleeding diathesis
- Arm B Criteria only: Clinically significant patient history which in the judgment of the principal investigator (PI) would compromise the subject's ability to tolerate high-dose aldesleukin;
- Any major bronchial occlusion or bleeding not amenable to palliation.
- Patients with psychiatric illness/social situations at the time of treatment that would limit compliance with study requirements.
- Participants with known active, uncontrolled bacterial, fungal, or viral infection
- Patients with a prior history or concurrent malignancy
- Active unstable or clinically significant medical condition
- History of any major cardiovascular conditions within the past 6 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: TCR-T Cell Drug Product
Phase I: Dose-escalation of TCR-T Cell Drug Product Phase II: Single dose of TCR-T Cell Drug Product after MTD/RP2D determine in Phase I portion of the study |
Phase I: Ascending dose, single Infusion of TCR+ Cells Phase II: Single infusion at the RP2D |
|
Experimental: TCR-T Cell Drug Product with Aldesleukin (IL-2)
Phase I: Dose-escalation of TCR-T Cell Drug Product with Aldesleukin (IL-2) Phase II: Single dose of TCR-T Cell Drug Product with Aldesleukin (IL-2) after MTD/RP2D determine in Phase I portion of the study |
Phase I: Ascending dose, single Infusion of TCR+ Cells Phase II: Single infusion at the RP2D To support growth and activation of TCR-T cell drug product |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Treatment-Emergent Adverse Events
Time Frame: From initiation of lymphodepletion through Day 28 after TCR-T cell infusion, and through long-term follow-up for up to 1 year.
|
Treatment-emergent adverse events (TEAEs) were defined as any adverse event that began or worsened after initiation of lymphodepletion and up to 28 days following TCR-T cell infusion. TEAEs were coded using MedDRA and summarized by system organ class and preferred term, severity, and relationship to study treatment. Participants were followed for delayed or ongoing toxicities for up to 1 year. |
From initiation of lymphodepletion through Day 28 after TCR-T cell infusion, and through long-term follow-up for up to 1 year.
|
|
Frequency of Dose Limiting Toxicities
Time Frame: From Day 0 to Day 28 post TCR-T cell drug product infusion.
|
Number of participants experiencing DLTs, defined as specific adverse events attributable to the TCR-T cell drug product occurring within the first 28 days of infusion. DLTs include, but are not limited to, Grade 4 neutropenia lasting ≥ 14 days, Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with significant bleeding, and ≥ Grade 3 febrile neutropenia with hemodynamic compromise. Non-hematologic DLTs include Grade 3 or 4 Cytokine Release Syndrome (CRS) that does not improve to Grade ≤ 2 within 72 hours, and Grade 3 Immune-effector cell-associated neurotoxicity syndrome (ICANS) that does not resolve to Grade ≤ 2 within 7 days, among others. The severity of adverse events will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. |
From Day 0 to Day 28 post TCR-T cell drug product infusion.
|
|
Determination of Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D)
Time Frame: From Day 0 to Day 28 post TCR-T cell drug product infusion.
|
MTD/RP2D determination was planned using accelerated escalation followed by the Bayesian Optimal Interval (BOIN) design and the protocol dose-escalation, de-escalation and stopping rules. Overt-toxicity criteria included 2 or more DLTs and consideration of longer-term toxicity. The trial would stop if the lowest dose was eliminated for overt toxicity. Formal MTD/RP2D determination was not completed because the study closed during Phase I Arm A. |
From Day 0 to Day 28 post TCR-T cell drug product infusion.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility of TCR-T Cell Drug Product Manufacturing
Time Frame: From apheresis collection to the release of the final TCR-T cell drug product for infusion, estimated to be approximately 5 weeks
|
Number of participants in each mutually exclusive leukapheresis and manufacturing disposition category. A full-scale run is a clinical drug-product manufacturing run; small-scale testing and cell enrichment or cryopreservation are not full-scale runs. All released products were infused. Final cell count and viability of released products are reported in separate outcome measures. |
From apheresis collection to the release of the final TCR-T cell drug product for infusion, estimated to be approximately 5 weeks
|
|
TCR-T Cell Persistence
Time Frame: Baseline through nominal Month 18 post-infusion.
|
Peripheral-blood TCR-T vector copy number (VCN) was measured by droplet digital PCR (ddPCR; LabCorp Drug Development) in copies per 1 × 10⁶ cells. Visits are nominal. One DL2 participant's nominal Day 28 and Week 6 samples were both collected on Day 44; the Month 18 sample was collected on Day 577. Samples after TCR001-201 exit were collected under TCR001-202 (NCT05292859). Summaries include quantifiable values only; not-detected and below-LLOQ values are excluded. NA indicates no quantifiable result. One post-dose Day 0 sample has identical copies/reaction and copies/mL values to another participant's sample; the copies per 1 × 10⁶ cells values differ. Sampling ended at disease progression, death or program closure. |
Baseline through nominal Month 18 post-infusion.
|
|
Percent Change in TCR-T Cell Count From Post Dose to Day 28
Time Frame: Post-dose Day 0 through nominal Day 28; nominal Day 28 samples were collected on actual Days 27 to 44.
|
For each participant, percent change from the highest post-dose VCN (copies per 1 × 10⁶ cells, ddPCR) from Day 0 post-dose through Day 21 to the nominal Day 28 value: ((Day 28 - peak) / peak) × 100. A Day 28 value below the LLOQ was set to 0 (-100%). |
Post-dose Day 0 through nominal Day 28; nominal Day 28 samples were collected on actual Days 27 to 44.
|
|
Final T-Cell Count in Released TCR-T Cell Drug Product
Time Frame: At release testing of the final infused lot before TCR-T cell infusion on Day 0; the lot was harvested 1 day before infusion (fresh product, 3 participants) or 30 to 156 days before infusion (cryopreserved product, 5 participants).
|
Final cell counts from the Certificate of Analysis for the released product administered to each participant. The two rows report total viable cells from the automated cell counter and final murine T-cell receptor-positive (mTCR+) cells from the Content-Calculation method, each in billions of cells. These are manufacturing results, not the administered dose. For participants with more than 1 manufacturing run, only the released lot is used. |
At release testing of the final infused lot before TCR-T cell infusion on Day 0; the lot was harvested 1 day before infusion (fresh product, 3 participants) or 30 to 156 days before infusion (cryopreserved product, 5 participants).
|
|
Viability of Released TCR-T Cell Drug Product
Time Frame: At release testing of the final infused lot before TCR-T cell infusion on Day 0; the lot was harvested 1 day before infusion (fresh product, 3 participants) or 30 to 156 days before infusion (cryopreserved product, 5 participants).
|
Percent viability reported on the final Certificate of Analysis for the released TCR-T cell product administered to each participant. One released product per participant is summarized, including the second manufacturing run when that run supplied the infused product. |
At release testing of the final infused lot before TCR-T cell infusion on Day 0; the lot was harvested 1 day before infusion (fresh product, 3 participants) or 30 to 156 days before infusion (cryopreserved product, 5 participants).
|
|
Protocol-Defined Duration of TCR-T Cell Persistence to the Last Quantifiable VCN Sample
Time Frame: From infusion through available VCN follow-up to nominal Month 18; last quantifiable samples were on Days 21 to 180.
|
Per Protocol Section 15.3.4 and SAP Section 4.5.2, duration is the number of days from infusion (Day 0) to the last sample with VCN at or above the assay lower limit of quantification. This is an observed last-quantifiable-sample metric. Sampling stopped at different times because of disease progression, death or program closure, so it does not establish when TCR-T cells disappeared. Later ND or below-LLOQ samples do not extend this metric. Samples from TCR001-202 are included where applicable. |
From infusion through available VCN follow-up to nominal Month 18; last quantifiable samples were on Days 21 to 180.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Scott Kopetz, MD, PhD, MD Anderson
Publications and helpful links
General Publications
- Levy PL, Gros A. Fast track to personalized TCR T cell therapies. Cancer Cell. 2022 May 9;40(5):447-449. doi: 10.1016/j.ccell.2022.04.013. Epub 2022 May 9.
- Morelli MP, Negrao MV, Collinson-Pautz MR, et al. Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors in first-in-human phase 1 study. J Clin Oncol. 2023;41(16_suppl):2547. doi:10.1200/JCO.2023.41.16_suppl.2547
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Endocrine System Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Intestinal Diseases
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Digestive System Diseases
- Gastrointestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Uterine Diseases
- Genital Diseases, Female
- Lung Diseases
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Colonic Diseases
- Lung Neoplasms
- Ovarian Diseases
- Adnexal Diseases
- Genital Neoplasms, Female
- Gonadal Disorders
- Carcinoma
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Uterine Neoplasms
- Adenocarcinoma of Lung
- Colorectal Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Cholangiocarcinoma
- Endometrial Neoplasms
- Peptides
- Amino Acids, Peptides, and Proteins
- Proteins
- Biological Factors
- Intercellular Signaling Peptides and Proteins
- Cytokines
- Interleukins
- Lymphokines
- Interleukin-2
- aldesleukin
Other Study ID Numbers
- TCR001-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.